Management of metabolic syndrome in young population

American Journal of Therapeutics

Volumn 15, Issue 4, 2008, Pages 356-361

  Brandão, Ayrton Pires ^a   Brandão, Andréa Araújo ^a   De Magalhães, Maria Eliane Campos ^a   Pozzan, Roberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardiovascular disease; Cardiovascular risk; Metabolic syndrome in young people; Overweight; Prevention

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; SATURATED FATTY ACID; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ARTICLE; ATHEROSCLEROSIS; AUTOPSY; BRAZIL; CALORIE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIFESTYLE; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; ADULT; AGE; CARDIOVASCULAR DISEASE; CHILD; DIET; EXERCISE; SMOKING;

ADOLESCENT; ADULT; AGE FACTORS; BRAZIL; CARDIOVASCULAR DISEASES; CHILD; DIET; EXERCISE; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SMOKING;

EID: 51649092868     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318164c107     Document Type: Article

References (39)

1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation. 2002;106:3143-3421.
3. Grundy SM, Brewer B, Cleeman JI, et al. Definition of the metabolic syndrome. Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109:433-138.
4. Brandão AP, Nogueira AR, Oliveira JE, et al. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol. 2005;84(Supll I):1-28.
5. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Eng J Med. 1998; 338:23:1650-1656.
6. Srinivasan SR, Myers L, Berenson GS. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (Syndrome X) in young adulthood: the Bogalusa Heart Study. Diabetes. 2002;51:204-209.
7. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes and cardiovascular risk in children. Circulation. 2003;107:1448-1453.
8. Chen W, Srinivasan SR, Elkasabany A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: The Bogalusa Heart Study. Atherosclerosis. 1999;145:197-205.
9. Berenson GS, Wattigney W, Tracy R, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol. 1992; 70:851-858.
10. Xiangrong L, Shengxu L, Ulosoy E, et al. Childhood adiposity as a predictor of cardiac mass in adulthood. The Bogalusa Heart Study. Circulation. 2004;110:3488-3492.
11. MacMahan CA, Gilding SS, Fayad ZA, et al. Risk score predict atherosclerotic lesions in young people. The Pathological Determinants of Atherosclerosis in Youth Research Group. Arch Intern Med. 2005;165:883-890.
12. Brandão AP, Brandão AA, Araujo EM, et al. The significance of physical development on blood pressure curve of children between 6 and 9 years of age and its relationship with familial aggregation. J Hypertens. 1989; 7(Suppl 1):S37-S39.
13. Brandão AP, Brandão AA, Araujo EMM, et al. Familial aggregation of arterial blood pressure and possible genetic influence. Hypertension. 1992;9(Suppl II):214-217.
14. Brandão AA, Pozzan R, Albanesi FM, et al. Role of anthropometric indexes and blood pressure as determinants of left ventricular mass and geometry in adolescents: the Rio de Janeiro Study. Hypertension. 1995;26: 1190-1194.
15. Magalhães ME, Pozzan R, Brandão AP, et al. Early blood pressure level as a mark of familial aggregation of metabolic cardiovascular risk factors: the Rio de Janeiro Study. J Hypertens. 1998;16:1885-1889.
16. Pozzan R, Brandão AA, Brandão AP, et al. Hyperglycemia, hyperinsulinemia, overweight, and high blood pressure in young adults: the Rio de Janeiro Study. Hypertension. 1997;30:650-653.
17. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
18. Instituto Brasileiro de Geografia e Estatística (IBGE) [website]. Análise da disponibilidade domiciliar de alimentos e do estado nutricional no Brasil. Available at: http://www.ibge.gov.br. Accessed 2005.
19. Monteiro CA, Mondini L, Souza AL, et al. The nutrition transition in Brazil. Eur J Clin Nutr. 1995;49:105-113.
20. Caballero B. Global health: a nutrition paradox underweight and obesity in developing countries. N Engl J Med. 2005;352:1514-1516.
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol. JAMA. 2001;285: 2486-2497.
22. Ard JD, Grambow SC, Liu D, et al. The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care. 2004;27:340-347.
23. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome: the optimal diet. Br J Nutr. 2000; 83(Suppl 1):S143-S148.
24. De Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454-1459.
25. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
26. Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev. 2000;28:165-170.
27. Grundy SM, Hansen B, Smith S Jr, et al. Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation. 2004;109:551-556.
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation. 2002;106:3143-3421.
29. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
30. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type diabetes. (UKPDS 38). BMJ. 1998;317:703-713.
31. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
32. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
33. Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders, ed 4. Alexandria, VA: American Diabetes Association, 2004.
34. Grundy SM, Hansen B, Smith S Jr, et al. Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation. 2004;109:551-556.
35. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
36. US National Institute of Health. Clinical Guidelines on the Identification, Evaluations and Treatment of Overweight and Obesity in Adults: executive summary. Expert Panel on the Identification, Evaluation and Treatment of Overweight in Adults. Am J Clin Nutr. 1998;68:899-917.
37. MacLean LD, Rhode BM, Sampolis J, et al. Results of the surgical treatment of obesity. Am J Surg. 1993;165:155-162.
38. Downey AM, Frank GC, Webber LS, et al. Implementation of "Heart Study": a cardiovascular school health promotion program. J Sch Health. 1987;57:98-104.
39. Hayman LL, Wiliams CL, Daniels SR, et al. Cardiovascular health promotion in the schools. Circulation. 2004; 110:2266-2275.